Vivani Medical (VANI) announced the successful administration of its first GLP-1 or exenatide, implant in the LIBERATE-1 clinical trial. This ...

FDA ends GLP-1 drug shortage. Concerns over safety, counterfeit drugs, and high cost of brand-name versions persist; ...

This month pharmacies will no longer be allowed to sell lower-cost compounded versions of the anti-obesity drug tirzepatide — ...

A product development expert explains how the swift rise of these anti-obesity medications is fueling new food trends.

While drug developers work to mitigate the side effects associated with GLP-1–based obesity drugs, recent studies reveal that ...

Nascent research into the link between gut health and brain function and the rise of GLP-1 weight-loss drugs could aid the ...

Polaris Market Research recently projected the global gummy market to reach $53.61 billion by 2032, nearly doubling its 2024 ...

Nearly one-third of adult employees would change jobs in order to gain coverage. As the demand for GLP-1 weight loss ...

Terns Pharmaceuticals is a small-cap biotech with a couple of weight loss candidates in its pipeline. The stock's price ...

Supergut is setting sights on bold retail expansion with the help of fresh capital and new executive leadership with a track ...

Gut health brand Supergut has secured new capital from Full Frame Growth Partners, and brought in former CEO of Vital Proteins as CEO.

Record Inventory Increase Meets Growing Consumer Demand for Healthcare Cost-Saving SolutionsSurge Driven by Ozempic and Zepbound Prescription ...